Dong Kwon Kim

Dong Kwon Kim

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
BABeung-Chul AHN
Beung-Chul AHN
JSJea-Woo So
Jea-Woo So
CSChun-Bong Synn
Chun-Bong Synn
TKTae Hyung Kim
Tae Hyung Kim
JKJae Hwan Kim
Jae Hwan Kim
HKHye Ryun Kim
Hye Ryun Kim

29 December 2021 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
CSChun‐Bong Synn
Chun‐Bong Synn
SKSung Eun Kim
Sung Eun Kim
HLHee Kyu Lee
Hee Kyu Lee
MKMin‐Hwan Kim
Min‐Hwan Kim
JKJae Hwan Kim
Jae Hwan Kim
BCByoung Chul Cho
Byoung Chul Cho
Objectives: AXL‐mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti‐tumor and anti‐metastatic activities of SKI‐G‐801, a small‐molecule inhibitor of AXL, alone and in combination with anti‐PD‐1 therapy.Methods: In vitro pAXL inhibition by SKI‐G‐801 was performed in both human and mouse cancer cell lines. Immunocompetent mouse models of tumor were established to measure anti‐metastatic potential of SKI‐G‐801. Furthermore, SKI‐G‐801, anti‐PD‐1 or their combination was administered as an adjuvant or neoadjuvant in the 4T1 tumor model to assess their potential for clinical application.Results: SKI‐G‐801 robustly inhibited pAXL expression in various cell lines. SKI‐G‐801 alone or in combination with anti‐PD‐1 potently inhibited metastasis in B16F10 melanoma, CT26 colon and 4T1 breast models. SKI‐G‐801 inhibited the growth of B16F10 and 4T1 tumor‐bearing mice but not immune‐deficient mice. An antibody depletion assay revealed that CD8+ T cells significantly contributed to SKI‐G‐801‐mediated survival. Anti‐PD‐1 and combination group were observed the increased CD8+Ki67+ and effector T cells and M1 macrophage and decreased M2 macrophage, and granulocytic myeloid‐derived suppressor cell (G‐MDSC) compared to the control group. The neoadjuvant combination of SKI‐G‐801 and anti‐PD‐1 therapy achieved superior survival benefits by inducing more profound T‐cell responses in the 4T1 syngeneic mouse model.Conclusion: SKI‐G‐801 significantly suppressed tumor metastasis and growth by enhancing anti‐tumor immune responses. Our results suggest that SKI‐G‐801 has the potential to overcome anti‐PD‐1 therapy resistance and allow more patients to benefit from anti‐PD‐1 therapy.

1 January 2024 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
YKYoungtaek Kim
Youngtaek Kim
JHJoon Yeon Hwang
Joon Yeon Hwang
KNKwangmin Na
Kwangmin Na
DKDong Kwon Kim
Dong Kwon Kim
SLSeul Lee
Seul Lee
KPKyoung-Ho Pyo
Kyoung-Ho Pyo
Kim Y, et al. Yonsei Med J. 2024 Sep;65:e67. https://doi.org/10.3349/ymj.2024.0062

1 July 2024 in Cancer Research Communications
Verified
Journal Article
Open access
SLSun Min Lim
Sun Min Lim
SKSeong-San Kang
Seong-San Kang
DKDong Kwon Kim
Dong Kwon Kim
SLSoo-Hwan Lee
Soo-Hwan Lee
CSChun-Bong Synn
Chun-Bong Synn
BCByoung Chul Cho
Byoung Chul Cho
Immune checkpoint inhibitors are effective first-line therapy for solid cancers. However, low response rate and acquired resistance over time has led to the need for additional therapeutic options. Here, we evaluated synergistic antitumor efficacy of EGFR × MET targeting bispecific antibody, amivantamab with PD-L1 immunotherapy, pembrolizumab in head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma tumor–bearing humanized patient-derived xenograft (PDX) models. We demonstrated that pembrolizumab or amivantamab alone was ineffective and that combination treatment induced a significant reduction of tumor growth in both models (P < 0.0001 and P < 0.01, respectively). It appeared that combination of amivantamab and pembrolizumab significantly enhanced infiltration of granzyme B–producing CD8 T cells was in the TME of HNSCC PDX (P < 0.01) and enhanced neoantigen-associated central memory CD8 T cells in circulating immune cells. Analysis of single-cell RNA transcriptomics suggested that the tumor cells dramatically upregulated EGFR and MET in response to PD-L1 immunotherapy, potentially creating a metabolic state fit for tumor persistence in the tumor microenvironment (TME) and rendered pembrolizumab ineffective. We demonstrated that EGFRHIGHMETHIGH subcluster displayed an increased expression of genes implicated in production of lactate [SLC16A3 and lactate dehydrogenase A (LDHA)] compared to the EGFRLOWMETLOW cluster. Accumulation of lactate in the TME has been associated with immunosuppression by hindering the infiltration of tumor killing CD8 T and NK cells. This study proved that amivantamab reduced glycolytic markers in the EGFRHIGHMETHIGH subcluster including SLC16A3 and LDHA and highlighted remodeling of the TME by combination treatment, providing rationale for additional therapy of amivantamab with PD-1 immunotherapy. Significance: Amivantamab in synergy with pembrolizumab effectively eradicated EGFRHIGHMETHIGH tumor subcluster in the tumor microenvironment of head and neck squamous cell carcinoma and overcame resistance against anti-PD-1 immunotherapy.

1 January 2022 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
CSChun-Bong Synn
Chun-Bong Synn
DKDong Kwon Kim
Dong Kwon Kim
JKJae Hwan Kim
Jae Hwan Kim
YBYoungseon Byeon
Youngseon Byeon
YKYoung Seob Kim
Young Seob Kim
KPKyoung-Ho Pyo
Kyoung-Ho Pyo
Synn CB, et al. Yonsei Med J. 2022 Jan;63(1):42-55. https://doi.org/10.3349/ymj.2022.63.1.42

5 December 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
DKDong Kwon Kim
Dong Kwon Kim
CSChun-Bong Synn
Chun-Bong Synn
WLWongeun Lee
Wongeun Lee
HJHa-Ni Jo
Ha-Ni Jo
CLChai Young Lee
Chai Young Lee
BCByoung Chul Cho
Byoung Chul Cho
Various combination therapies have been investigated to overcome the limitations of using immune checkpoint inhibitors. However, determining the optimal combination therapy remains challenging. To overcome the therapeutic limitation, we conducted a translational research to elucidate the mechanisms by which AXL inhibition enhances antitumor effects when combined with anti–PD-1 antibody therapy. Herein, we demonstrated improved antitumor effects through combination treatment with denfivontinib and pembrolizumab which resulted in enhanced differentiation into effector CD4+ and CD8+ memory T cells, accompanied by an increase in IFN-γ expression in the YHIM-2004 xenograft model derived from patients with non–small cell lung cancer. Concurrently, a reduction in the number of immunosuppressive M2 macrophages and myeloid-derived suppressor cells was observed. Mechanistically, denfivontinib potentiated the NOD-like receptor pathway, thereby facilitating NLRP3 inflammasome formation. This leads to macrophage activation via NF-κB signaling pathway activation. We have confirmed that the positive interaction between macrophages and T cells arises from the enhanced antigen-presenting machinery of activated macrophages. Furthermore, the observed tumor effects in AXL knockout mice confirmed that AXL inhibition by denfivontinib enhances the antitumor effects, thus opening new avenues for therapeutic interventions aimed at overcoming limitations in immunotherapy. To demonstrate the extent to which our findings reflect clinical results, we analyzed bulk RNA sequencing data from 21 patients with non–small cell lung cancer undergoing anti–PD-1 immunotherapy. The NLRP3 inflammasome score influenced enhanced immune responses in patient data undergoing anti–PD-1 immunotherapy, suggesting a role for the NLRP3 inflammasome in activating immune responses during treatment.